The role of vitamin D in atherosclerosis inflammation revisited: More a bystander than a player?

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 392-398

  Mangge, Harald ^a   Weghuber, Daniel ^b   Prassl, Ruth ^a   Haara, Astrid ^c   Schnedl, Wolfgang ^d   Postolache, Teodor T ^e   Fuchs, Dietmar ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Paracelsus Private Medical School Salzburg   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d General Practice for Internal Medicine   (Austria)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Immune mediated inflammation; Therapeutic potential; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA DEFENSIN 1; CALCITRIOL; COLECALCIFEROL; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 6; NEOPTERIN; PARICALCITOL; TUMOR NECROSIS FACTOR; VITAMIN D; HYDROXYCOLECALCIFEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CD4+ CD25+ T LYMPHOCYTE; CORONARY ARTERY DISEASE; DOWN REGULATION; FEEDBACK SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MORBIDITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; UPREGULATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; HUMANS; HYDROXYCHOLECALCIFEROLS; INFLAMMATION; VITAMIN D;

EID: 84937149141     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111666131209125454     Document Type: Article

References (84)

1. [1] Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol 2011; 58(15): 1547-56.
2. [2] Autier P, Gandini S, Mullie P. A systematic review: influence of vitamin D supplementation on serum 25-hydroxyvitamin D concentration. J Clin Endocrinol Metab 2012; 97(8): 2606-13.
3. [3] Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
4. [4] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911-30.
5. [5] Kox M, van den Berg MJ, van der Hoeven JG, Wielders JP, van der Ven AJ, Pickkers P. Vitamin D status is not associated with inflammatory cytokine levels during experimental human endotoxaemia. Clin Exp Immunol 2013; 171(2): 231-6.
6. [6] Gonzalez-Parra E, Rojas-Rivera J, Tunon J, Praga M, Ortiz A, Egido J. Vitamin D receptor activation and cardiovascular disease. Nephrol Dial Transplant 2012; 27(Suppl 4): 17-21.
7. [7] Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15): 1629-37.
8. [8] Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Rheum Dis Clin North Am 2012; 38(1): 125-39.
9. [9] Flynn L, Zimmerman LH, McNorton K, et al. Effects of vitamin D deficiency in critically ill surgical patients. Am J Surg 2012; 203(3): 379-82; discussion 382.
10. [10] Weng S, Sprague JE, Oh J, et al. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS One 2013; 8(1): e54625.
11. [11] Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol 2013; 28(3): 205-21.
12. [12] Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2011; 29(4): 636-45.
13. [13] Song Y, Wang L, Pittas AG, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 2013; 36(5): 1422-18.
14. [14] Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc 2013; 72(1): 89-97.
15. [15] Makariou S, Liberopoulos E, Florentin M, et al. The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci 2012; 8(3): 437-43.
16. [16] Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014; 12(4): 627-41.
17. [17] Dasarathy J, Periyalwar P, Allampati S, et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int 2014; 34(6): e118-27.
18. [18] Maki KC, Fulgoni VL, 3rd, Keast DR, Rains TM, Park KM, Rubin MR. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: National Health and Nutrition Examination Surveys 2003-2006. Metab Syndr Relat Disord 2012; 10(5): 363-72.
19. [19] Querfeld U. Vitamin D and inflammation. Pediatr Nephrol 2013; 28(4): 605-10.
20. [20] Richards JB, Valdes AM, Gardner JP, et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am J Clin Nutr 2007; 86(5): 1420-5.
21. [21] Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294(5): F1059-64.
22. [22] Oh J, Weng S, Felton SK, et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009; 120(8): 687-98.
23. [23] Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25(3): 320-5.
24. [24] Dyer CA. Safety and tolerability of paricalcitol in patients with chronic kidney disease. Expert Opin Drug Saf 2013; 12(5): 717-28.
25. [25] Petchey WG, Johnson DW, Isbel NM. Shining D’ light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton) 2011; 16(4): 351-67.
26. [26] Lavie CJ, Dinicolantonio JJ, O’Keefe JH, Milani RV. Vitamin D status, left ventricular geometric abnormalities and cardiovascular disease. J Intern Med 2013; 273(3): 246-8.
27. [27] Yiu YF, Yiu KH, Siu CW, et al. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis 2013; 227(1): 140-146.
28. [28] Carrillo AE, Flynn MG, Pinkston C, et al. Vitamin D supplementation during exercise training does not alter inflammatory biomarkers in overweight and obese subjects. Eur J Appl Physiol 2012; 112(8): 3045-52.
29. [29] Carrillo AE, Flynn MG, Pinkston C, et al. Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults. Clin Nutr 2013; 32(3): 375-81.
30. [30] Sokol SI, Srinivas V, Crandall JP, et al. The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med 2012; 17(6): 394-404.
31. [31] Manson JE, Allison MA, Carr JJ, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause 2010; 17(4): 683-91.
32. [32] Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension 2008; 52(5): 847-55.
33. [33] Rajpathak SN, Xue X, Wassertheil-Smoller S, et al. Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women’s Health Initiative. Am J Clin Nutr 2010; 91(4): 894-9.
34. [34] Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115(7): 846-54.
35. [35] Witham MD, Price RJ, Struthers AD, et al. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Intern Med 2013; 173(18): 1672-9.
36. [36] Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010; 17(36): 4511-20.
37. [37] Mangge H, Hubmann H, Pilz S, Schauenstein K, Renner W, Marz W. Beyond cholesterol--inflammatory cytokines, the key mediators in atherosclerosis. Clin Chem Lab Med 2004; 42(5): 467-74.
38. [38] Khoo AL, Chai LY, Koenen HJ, et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011; 164(1): 72-9.
39. [39] Khoo AL, Chai LY, Koenen HJ, et al. 1,25-dihydroxyvitamin D3 modulates cytokine production induced by Candida albicans: impact of seasonal variation of immune responses. J Infect Dis 2011; 203(1): 122-30.
40. [40] Maruotti N, Cantatore FP. Vitamin D and the immune system. J Rheumatol 2010; 37(3): 491-5.
41. [41] Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA 2011; 305(24): 2565-6.
42. [42] Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96(1): 53-8.
43. [43] Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 2002; 195(5): 603-16.
44. [44] Gorman S, Kuritzky LA, Judge MA, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007; 179(9): 6273-83.
45. [45] Urry Z, Xystrakis E, Richards DF, et al. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 2009; 119(2): 387-98.
46. [46] Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121(1-2): 193-8.
47. [47] Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor kappaB activation by interacting with IkappaB kinase beta protein. J Biol Chem 2013; 288(27): 19450-8.
48. [48] Shuler FD, Hendrix J, Hodroge S, Short A. Antibiotic-like actions of vitamin D. W V Med J 2013; 109(1): 22-5.
49. [49] Rees JR, Hendricks K, Barry EL, et al. Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial. Clin Infect Dis 2013; 57(10): 1384-92.
50. [50] Neurauter G, Schrocksnadel K, Scholl-Burgi S, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008; 9(7): 622-7.
51. [51] Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 2010; 24(3): 403-8.
52. [52] Murr C, Pilz S, Grammer TB, et al. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med 2012; 50(12): 2205-12.
53. [53] Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000; 85(5): 1834-40.
54. [54] Schroeder BO, Wu Z, Nuding S, et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human betadefensin 1. Nature 2011; 469(7330): 419-23.
55. [55] Leblhuber F, Schneider A, Schroecksnadel S, Brunschutz D, Steiner K, Fuchs D. Vitamin D and tryptophan concentrations in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2013; 28(2): 216-7.
56. [56] Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis 1994; 169(4): 889-93.
57. [57] Huber C, Batchelor JR, Fuchs D, et al. Immune responseassociated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160(1): 310-6.
58. [58] Murr C, Winklhofer-Roob BM, Schroecksnadel K, et al. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009; 202(2): 543-9.
59. [59] Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Fuchs D. Neopterin derivatives modulate the nitration of tyrosine by peroxynitrite. Biochem Biophys Res Commun 1998; 248(2): 341-6.
60. [60] Kapiotis S, Holzer G, Schaller G, et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol 2006; 26(11): 2541-6.
61. [61] Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 2004; 112(7): 378-82.
62. [62] Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 2012; 36(3): 387-96.
63. [63] Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72(3): 690-3.
64. [64] Li J, Byrne ME, Chang E, et al. 1alpha,25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol 2008; 112(1-3): 122-6.
65. [65] Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17(7): 517-24.
66. [66] Compher CW, Badellino KO, Boullata JI. Vitamin D and the bariatric surgical patient: a review. Obes Surg 2008; 18(2): 220-4.
67. [67] Sochorova K, Budinsky V, Rozkova D, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009; 133(1): 69-77.
68. [68] Mangge H, Summers KL, Meinitzer A, et al. Obesity-related dysregulation of the Tryptophan-Kynurenine metabolism: Role of age and parameters of the metabolic syndrome. Obesity (Silver Spring) 2014; 22(1): 195-201.
69. [69] Olson NC, Sallam R, Doyle MF, Tracy RP, Huber SA. T helper cell polarization in healthy people: implications for cardiovascular disease. J Cardiovasc Transl Res 2013; 6(5): 772-86.
70. [70] Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity, the role of interleukin-10. Front Immunol 2013; 4: 129.
71. [71] Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost 2011; 106(5): 779-86.
72. [72] Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 2003; 30(11): 2506-7.
73. [73] Bansal AS, Henriquez F, Sumar N, Patel S. T helper cell subsets in arthritis and the benefits of immunomodulation by 1,25(OH)(2) vitamin D. Rheumatol Int 2012; 32(4): 845-52.
74. [74] Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993; 101(1): 1-6.
75. [75] Kohl C, Walch T, Huber R, et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord 2005; 86(2-3): 135-42.
76. [76] Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski JC. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 2009; 16(35): 4644-53.
77. [77] Girgin G, Sahin TT, Fuchs D, et al. Tryptophan degradation and serum neopterin concentrations in intensive care unit patients. Toxicol Mech Methods 2011; 21(3): 231-5.
78. [78] Edfeldt K, Liu PT, Chun R, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 2010; 107(52): 22593-8.
79. [79] Jirapongsananuruk O, Melamed I, Leung DY. Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses. J Allergy Clin Immunol 2000; 106(5): 981-5.
80. [80] Helming L, Bose J, Ehrchen J, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106(13): 4351-8.
81. [81] Riek AE, Oh J, Sprague JE, et al. Vitamin D suppression of endoplasmic reticulum stress promotes an antiatherogenic monocyte/ macrophage phenotype in type 2 diabetic patients. J Biol Chem 2012; 287(46): 38482-94.
82. [82] Riek AE, Oh J, Bernal-Mizrachi C. Vitamin D regulates macrophage cholesterol metabolism in diabetes. J Steroid Biochem Mol Biol 2010; 121(1-2): 430-3.
83. [83] Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134(6): 1129-40.
84. [84] Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol 2009; 31(1): 23-3